A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk.

Troy BremerPat W WhitworthRakesh PatelJess SavalaTodd BarryStephen LyleGlen LeesmanSteven P LinkeKarin JirströmWenjing ZhouRose-Marie AminiFredrik Wärnberg

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

The DS was prognostic for risk and predicted RT benefit for DCIS patients. DS identified a clinically meaningful low-risk group and a group with elevated 10-year risks that received substantial RT benefit over baseline.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
radiation therapy
patient reported outcomes
locally advanced
rectal cancer
climate change